Cytosorbents corporation stock
WebNov 3, 2024 · PRNewswire/ -- CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2024 financial results after the market close on … WebA. The Company and the Investor are parties to a Purchase Agreement dated as of May 5, 2010 (the “ Purchase Agreement ”), pursuant to which, among other things, the Company has the right to sell to the Investor, at its sole discretion, up to $6,000,000 of the Company’s common stock, par value $0.001 per share (“ Common Stock ”), upon ...
Cytosorbents corporation stock
Did you know?
WebEX-4.1 2 v357112_ex4-1.htm EXHIBIT 4.1 . CONVERTIBLE NOTE (FOR DISCUSSION PURPOSES ONLY – NOT FOR SOLICITATION) $ _____ Maturity Date : 12 Months from Note closing date . FOR VALUE RECEIVED, the undersigned CytoSorbents Corporation (the “Company”), promises to pay in equity as set forth below on or before xx/xx/xx, … WebMar 9, 2024 · Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript ... Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank ...
WebSep 30, 2013 · This is to certify that, FOR VALUE RECEIVED, _____ or assigns (“Holder”), is entitled to purchase, subject to the provisions of this Warrant, from CYTOSORBENTS CORPORATION, a NEVADA corporation (the “Company”), _____ fully paid, validly issued and nonassessable shares of Common Stock, $.001 par value, of the Company at a … Web2.3 Company 2013 Performance-based Stock Option Grant. In addition to the above, the Employee will be entitled to an option grant to purchase 500,000 shares of the Company’s common stock, that vests piecemeal with the achievement of pre-determined milestones approved by the BOD priced at the 5-day VWAP at the time of BOD approval of the …
WebCOVID-19 put spotlight on their flagship product Cytosorb, as it gained emergency FDA approval for treatment of severe COVID-19 patients. As further approvals for removal of ticagrelor and rivaroxaban have followed, Cytosorb Summary Target $30, Stop $5. (Analyst price-targets around $14-$17). WebJul 22, 2024 · --CytoSorbents Corporation, ... today announced the pricing of its previously announced underwritten public offering of 5,263,158 shares of its common stock at a public offering price of $9. ...
WebApr 6, 2024 · CTSO Stock Overview. Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally.
WebApr 6, 2024 · CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its polymer … north clinic osseo appointmentsWebMar 10, 2024 · The low in the last 52 weeks of Cytosorbents stock was 1.03. According to the current price, Cytosorbents is 347.57% away from the 52-week low. What was the 52-week high for Cytosorbents stock? north clinic in robbinsdaleWebApr 8, 2024 · Cytosorbents Corporation (NASDAQ:CTSO)’s traded shares stood at 88732.0 during the last session, with the company’s beta value hitting 0.75. At the close of trading, the stock’s price was $3.19, to imply a decrease of -2.74% or -$0.09 in intraday trading. The CTSO share’s 52-week high remains $4.59, putting it -43.89% down since … north clinic elk river mnWebFeb 15, 2024 · Cytosorbents Corporation Common Stock (CTSO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Skip … north clinic osseo doctorsWebFeb 21, 2024 · Insiders At Cytosorbents Have Bought Stock Recently We saw some Cytosorbents insider buying shares in the last three months. CEO & Director Phillip Chan shelled out US$38k for shares in that time. north clinic plymouth providersWebStock Quote. NASDAQCTSO. $1.90. -0.10. expand. Currency in USD. Quote data delayed by at least 15 minutes. CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders. north clinic seattle children\u0027sWebSep-14-22 06:39AM. Great news for Cytosorbents Corporation (NASDAQ:CTSO): Insiders acquired stock in large numbers last year. Simply Wall St. Sep-09-22 07:00AM. The U.S. Department of Defense Awards CytoSorbents an Approximately $2.0M Contract to Support HemoDefend-BGA Development for Life-saving Universal Plasma. how to reset password on nintendo switch